As discussed below, GLP-1 RAs have beneficial effects on atherosclerotic cardiovascular disease, heart failure, renal disease, metabolic dysfunction associated steatotic liver disease (MASLD), osteoarthritis, etc
The FDA has received 605 reports of adverse events associated with compounded semaglutide and 545 reports of adverse events associated with compounded tirzepatide (as of July 31, 2025)
Food and Drug Administration (FDA) hasnt approved any weight loss patches that work like the blockbuster injected GLP-1 drugs Ozempic, Wegovy, Zepbound, and Mounjaro, says Jody Dushay, MD, an assistant professor at Harvard Medical School and an endocrinologist at Beth Israel Deaconess Medical Center in Boston
Peptide-related therapies discussed on this website may not be approved by the U.S